Circulating malondialdehyde-modified low-density lipoprotein is strongly associated with very small low-density lipoprotein cholesterol concentrations in healthy men

Clinica Chimica Acta

Volumn 399, Issue 1-2, 2009, Pages 74-78

  Takahashi, Ryotaro ^a   Imamura, Akiko ^b   Yoshikane, Mari ^a   Suzuki, Masayuki ^a   Cheng, Xian Wu ^c   Numaguchi, Yasushi ^b   Ikeda, Nobuo ^a   Murohara, Toyoaki ^b   Okumura, Kenji ^c  

^a Chunichi Hospital   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

High performance liquid chromatography; Lipoprotein subclass; Malondialdehyde modified LDL; Oxidized LDL; Very small LDL cholesterol

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONDIALDEHYDE MODIFIED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY SMALL LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; JAPAN; LEUKOCYTE COUNT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, VLDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEALTH; HUMANS; INSULIN; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; REFERENCE VALUES; REGRESSION ANALYSIS; TRIGLYCERIDES; URIC ACID; WAIST CIRCUMFERENCE; WAIST-HIP RATIO;

EID: 57049111493     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.09.015     Document Type: Article

References (39)

1. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
2. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., and Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
3. Campos H., Genest Jr. J.J., Blijlevens E., et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12 (1992) 187-195
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
5. Krauss R.M., and Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23 (1982) 97-104
6. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48 (2002) 171-180
7. Okazaki M., Usui S., Ishigami M., et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 25 (2005) 578-584
8. Usui S., Hara Y., Hosaki S., and Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 43 (2002) 805-814
9. Hazen S.L., and Chisolm G.M. Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response. Proc Natl Acad Sci U S A 99 (2002) 12515-12517
10. Yoshida H., Sasaki K., Namiki Y., Sato N., and Tada N. Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis 179 (2005) 97-102
11. Mizuno T., Matsui H., Imamura A., et al. Insulin resistance increases circulating malondialdehyde-modified LDL and impairs endothelial function in healthy young men. Int J Cardiol 97 (2004) 455-461
12. Ehara S., Ueda M., Naruko T., et al. Increased concentrations of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
13. Ishigaki Y., Katagiri H., Gao J., et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118 (2008) 75-83
14. Kitano S., Kanno T., Maekawa M., et al. Improved method for the immunological detection of malondialdehyde-modified low-density lipoproteins in human serum. Anal Chim Acta 509 (2004) 229-235
15. Kotani K., Maekawa M., Kanno T., Kondo A., Toda N., and Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215 (1994) 121-125
16. Torigoe M., Matsui H., Ogawa Y., et al. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men. Clin Endocrinol (Oxf) 67 (2007) 276-281
17. Aso Y., Yamamoto R., Wakabayashi S., et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55 (2006) 1954-1960
18. Oda E., and Watanabe K. Japanese criteria of metabolic syndrome. Circ J 70 (2006) 364
19. Shen M.M., Krauss R.M., Lindgren F.T., and Forte T.M. Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res 22 (1981) 236-244
20. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 95 (1997) 69-75
21. Fogelman A.M., Shechter I., Seager J., Hokom M., Child J.S., and Edwards P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A 77 (1980) 2214-2218
22. Bevan R.J., Durand M.F., Hickenbotham P.T., et al. Validation of a novel ELISA for measurement of MDA-LDL in human plasma. Free Radic Biol Med 35 (2003) 517-527
23. Kondo A., Manabe M., Saito K., Maekawa M., and Kanno T. Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes. J Atheroscler Thromb 9 (2002) 280-287
24. Ndrepepa G., Braun S., von Beckerath N., et al. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clin Chim Acta 360 (2005) 178-186
25. Sigurdardottir V., Fagerberg B., and Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 252 (2002) 440-447
26. Sjogren P., Basu S., Rosell M., et al. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not increased in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 25 (2005) 2580-2586
27. Ziedén B., Kaminskas A., Kristenson M., Olsson A.G., and Kucinskiene Z. Long chain polyunsaturated fatty acids may account for higher low-density lipoprotein oxidation susceptibility in Lithuanian compared to Swedish men. Scand J Clin Lab Invest 62 (2002) 307-314
28. Ceconi C., Cargnoni A., Pasini E., Condorelli E., Curello S., and Ferrari R. Evaluation of phospholipid peroxidation as malondialdehyde during myocardial ischemia and reperfusion injury. Am J Physiol 260 (1991) H1057-H1061
29. Campos H., Arnold K.S., Balestra M.E., Innerarity T.L., and Krauss R.M. Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol 16 (1996) 794-801
30. Krauss R.M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 5 (1994) 339-349
31. Tribble D.L., Rizzo M., Chait A., Lewis D.M., Blanche P.J., and Krauss R.M. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 110 (2001) 103-110
32. Miller N.E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 113 (1987) 589-597
33. Upton G.V. Lipids, cardiovascular disease, and oral contraceptives: a practical perspective. Fertil Steril 53 (1990) 1-12
34. Kempen H.J., van Gent C.M., Buytenhek R., and Buis B. Association of cholesterol concentrations in low-density lipoprotein, high-density lipoprotein, and high-density lipoprotein subfractions, and of apolipoproteins AI and AII, with coronary stenosis and left ventricular function. J Lab Clin Med 109 (1987) 19-26
35. Miller N.E., Hammett F., Saltissi S., et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J (Clin Res Ed) 282 (1981) 1741-1744
36. Holvoet P., Lee D.H., Steffes M., Gross M., and Jacobs Jr. D.R. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299 (2008) 2287-2293
37. Rivellese A.A., Patti L., Kaufman D., et al. Lipoprotein particle distribution and size, insulin resistance, and metabolic syndrome in Alaska Eskimos: The GOCADAN study. Atherosclerosis 200 (2008) 350-358
38. de Souza J.A., Vindis C., Hansel B., et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 197 (2008) 84-94
39. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein concentration. J Am Coll Cardiol 47 (2006) 338-341